UNCY Valuation
Unicycive Therapeutics Inc
$
4.620
UNCY Relative Valuation
UNCY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, UNCY is overvalued; if below, it's undervalued.
Historical Valuation
Unicycive Therapeutics Inc (UNCY) is now in the Fair zone, suggesting that its current forward PS ratio of 4.58 is considered Fairly compared with the five-year average of -0.51. The fair price of Unicycive Therapeutics Inc (UNCY) is between 1.05 to 5.69 according to relative valuation methord.
Relative Value
Fair Zone
1.05-5.69
Current Price：4.62
Fair
2.73
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Unicycive Therapeutics Inc. (UNCY) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -6302.41. The thresholds are as follows: Strongly Undervalued below -64374.64, Undervalued between -64374.64 and -35338.52, Fairly Valued between 22733.71 and -35338.52, Overvalued between 22733.71 and 51769.83, and Strongly Overvalued above 51769.83. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
1.93
EV/EBIT
Unicycive Therapeutics Inc. (UNCY) has a current EV/EBIT of 1.93. The 5-year average EV/EBIT is -1.12. The thresholds are as follows: Strongly Undervalued below -4.79, Undervalued between -4.79 and -2.95, Fairly Valued between 0.71 and -2.95, Overvalued between 0.71 and 2.54, and Strongly Overvalued above 2.54. The current Forward EV/EBIT of 1.93 falls within the Overvalued range.
4.58
PS
Unicycive Therapeutics Inc. (UNCY) has a current PS of 4.58. The 5-year average PS is 4.62. The thresholds are as follows: Strongly Undervalued below -20.15, Undervalued between -20.15 and -7.77, Fairly Valued between 17.00 and -7.77, Overvalued between 17.00 and 29.38, and Strongly Overvalued above 29.38. The current Forward PS of 4.58 falls within the Historic Trend Line -Fairly Valued range.
-1.87
P/OCF
Unicycive Therapeutics Inc. (UNCY) has a current P/OCF of -1.87. The 5-year average P/OCF is 11.95. The thresholds are as follows: Strongly Undervalued below -78.47, Undervalued between -78.47 and -33.26, Fairly Valued between 57.15 and -33.26, Overvalued between 57.15 and 102.36, and Strongly Overvalued above 102.36. The current Forward P/OCF of -1.87 falls within the Historic Trend Line -Fairly Valued range.
-2.89
P/FCF
Unicycive Therapeutics Inc. (UNCY) has a current P/FCF of -2.89. The 5-year average P/FCF is -0.67. The thresholds are as follows: Strongly Undervalued below -7.70, Undervalued between -7.70 and -4.19, Fairly Valued between 2.85 and -4.19, Overvalued between 2.85 and 6.36, and Strongly Overvalued above 6.36. The current Forward P/FCF of -2.89 falls within the Historic Trend Line -Fairly Valued range.
Unicycive Therapeutics Inc (UNCY) has a current Price-to-Book (P/B) ratio of 3.93. Compared to its 3-year average P/B ratio of -1.90 , the current P/B ratio is approximately -307.49% higher. Relative to its 5-year average P/B ratio of -1.24, the current P/B ratio is about -416.28% higher. Unicycive Therapeutics Inc (UNCY) has a Forward Free Cash Flow (FCF) yield of approximately -41.03%. Compared to its 3-year average FCF yield of -72.95%, the current FCF yield is approximately -43.75% lower. Relative to its 5-year average FCF yield of -65.00% , the current FCF yield is about -36.88% lower.
3.93
P/B
Median3y
-1.90
Median5y
-1.24
-41.03
FCF Yield
Median3y
-72.95
Median5y
-65.00
Competitors Valuation Multiple
The average P/S ratio for UNCY's competitors is 2.84, providing a benchmark for relative valuation. Unicycive Therapeutics Inc Corp (UNCY) exhibits a P/S ratio of 4.58, which is 61.15% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of UNCY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of UNCY in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is Unicycive Therapeutics Inc (UNCY) currently overvalued or undervalued?
Unicycive Therapeutics Inc (UNCY) is now in the Fair zone, suggesting that its current forward PS ratio of 4.58 is considered Fairly compared with the five-year average of -0.51. The fair price of Unicycive Therapeutics Inc (UNCY) is between 1.05 to 5.69 according to relative valuation methord.
What is Unicycive Therapeutics Inc (UNCY) fair value?
How does UNCY's valuation metrics compare to the industry average?
What is the current P/B ratio for Unicycive Therapeutics Inc (UNCY) as of Nov 08 2025?
What is the current FCF Yield for Unicycive Therapeutics Inc (UNCY) as of Nov 08 2025?
What is the current Forward P/E ratio for Unicycive Therapeutics Inc (UNCY) as of Nov 08 2025?